Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 330 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR “My First Thought Was My Children:” Young Mom Diagnosed With Triple-Negative... July 20, 2020 Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation... March 2, 2026 AI and remote monitoring are shaping a new patient journey in... August 26, 2025 2023 ASCO Annual Meeting Research Round Up: Advances in Treating Gynecologic... August 17, 2023 Load more HOT NEWS Hero Nanny Permanently Injured While Saving 2-Year-Old From Speeding Car About... FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... ¿Puede el uso de un microondas causar cáncer?
